Loxo, Bayer biomarker-driven drug maintains high response rates in ESMO presentation
Larotrectinib showed an 81 percent response rate among 109 patients with NTRK fusion-positive cancers, with most continuing to respond or receiving surgery with curative intent after more than a year.